PURPOSE: Series of N,N-dimethylamino acid esters was synthesized to study their transdermal permeation-enhancing potency, biodegradability and reversibility of action. Effects of chirality, linking chain length and polyfluorination were investigated. MATERIALS AND METHODS: In vitro activities were evaluated using porcine skin and four model drugs-theophylline, hydrocortisone, adefovir and indomethacin. Biodegradability was determined using porcine esterase, reversibility was measured using electrical resistance. RESULTS: No differences in activity were found between (R), (S) and racemic dodecyl 2-(dimethylamino)propanoate (DDAIP). Substitution of hydrocarbon tail by fluorocarbon one resulted in loss of activity. Replacement of branched linking chain between nitrogen and ester of DDAIP by linear one markedly improved penetration-enhancing activity with optimum in 4-6C acid derivatives. Dodecyl 6-(dimethylamino)hexanoate (DDAK) was more potent than clinically used skin absorption enhancer DDAIP for theophylline (enhancement ratio of DDAK and DDAIP was 17.3 and 5.9, respectively), hydrocortisone (43.2 and 11.5) and adefovir (13.6 and 2.8), while DDAIP was better enhancer for indomethacin (8.7 and 22.8). DDAK was rapidly metabolized by porcine esterase, and displayed low acute toxicity. Electrical resistance of DDAK-treated skin barrier promptly recovered to control values. CONCLUSION: DDAK, highly effective, broad-spectrum, biodegradable and reversible transdermal permeation enhancer, is promising candidate for future research.

Centre for New Antivirals and Antineoplastics Department of Inorganic and Organic Chemistry Faculty of Pharmacy Hradec Králové Charles University Prague Heyrovského 1203 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Pharm Res. 1994 Feb;11(2):288-94 PubMed

J Org Chem. 1996 May 31;61(11):3849-3862 PubMed

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1712-5 PubMed

Adv Drug Deliv Rev. 2004 Mar 27;56(5):603-18 PubMed

Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):43-52 PubMed

Bioorg Med Chem. 2006 Dec 1;14(23):7681-7 PubMed

Arch Dermatol Res. 2002 Nov;294(8):383-5 PubMed

Drug Discov Today. 2004 Aug 15;9(16):697-703 PubMed

Curr Med Chem. 2005;12(19):2273-91 PubMed

Skin Res Technol. 2007 Feb;13(1):19-24 PubMed

Curr Med Chem. 2000 Jun;7(6):593-608 PubMed

Eur J Pharm Biopharm. 2008 Jun;69(2):597-604 PubMed

J Biophys Biochem Cytol. 1955 Jan;1(1):13-6 PubMed

Pharm Res. 2006 May;23(5):912-9 PubMed

Skin Pharmacol Physiol. 2007;20(6):272-82 PubMed

J Med Chem. 1999 Jun 17;42(12):2064-86 PubMed

Pharmazie. 2000 Oct;55(10):759-61 PubMed

J Pharm Sci. 2004 Mar;93(3):762-79 PubMed

J Med Chem. 1991 Mar;34(3):1024-7 PubMed

Pharm Res. 2006 Jul;23(7):1517-24 PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):198-203 PubMed

Toxicol In Vitro. 2004 Jun;18(3):351-8 PubMed

Pharm Res. 1993 Nov;10(11):1632-7 PubMed

J Control Release. 2005 May 5;104(1):41-9 PubMed

Pharm Res. 1989 Mar;6(3):244-7 PubMed

J Pharm Sci. 2005 Jul;94(7):1494-9 PubMed

Nat Rev Drug Discov. 2004 Feb;3(2):115-24 PubMed

Eur J Pharm Biopharm. 2008 Nov;70(3):901-7 PubMed

Int J Pharm. 2004 Mar 1;271(1-2):5-10 PubMed

Toxicol Sci. 2006 Jun;91(2):341-55 PubMed

Biopolymers. 2002;67(4-5):285-8 PubMed

Pharm Res. 2006 Aug;23(8):1850-6 PubMed

Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers

Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers

Galactosyl Pentadecene Reversibly Enhances Transdermal and Topical Drug Delivery

Dodecyl Amino Glucoside Enhances Transdermal and Topical Drug Delivery via Reversible Interaction with Skin Barrier Lipids

Transdermal delivery and cutaneous targeting of antivirals using a penetration enhancer and lysolipid prodrugs

Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP